Skip to menu Skip to content Skip to footer
Dr Drew Neavin
Dr

Drew Neavin

Email: 

Overview

Background

Dr Drew Neavin is an NHMRC Early Leadership Fellow and the Group Leader of the Context-dependent Genetics Lab at the University of Queensland Institute for Molecular Bioscience.

Drew integrates statistical genetics with stem cell platforms and single-cell technologies to expand our understanding of genetic regulation across different contexts. She helped establish "village-in-a-dish" stem cell systems that enable high-throughput stem cell culture while reducing technical variability by co-culturing induced pluripotent stem cell lines from hundreds of individuals in a single cell culture dish. She applies this system along with other experimental models to study genetic regulation. She works across multiple disease systems with focuses in neuopsychiatric and cardiac, with a special focus on genetic modulation of drug response. She is keen to build large-scale resources that enable population genetics interrogation that consider diversity across multiple different axes.

Availability

Dr Drew Neavin is:
Available for supervision

Works

Search Professor Drew Neavin’s works on UQ eSpace

24 works between 2018 and 2026

21 - 24 of 24 works

2019

Journal Article

Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication

Athreya, Arjun P., Neavin, Drew, Carrillo-Roa, Tania, Skime, Michelle, Biernacka, Joanna, Frye, Mark A., Rush, A. John, Wang, Liewei, Binder, Elisabeth B., Iyer, Ravishankar K., Weinshilboum, Richard M. and Bobo, William V. (2019). Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication. Clinical Pharmacology and Therapeutics, 106 (4), 855-865. doi: 10.1002/cpt.1482

Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication

2019

Journal Article

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients

Bhattacharyya, Sudeepa, Ahmed, Ahmed T., Arnold, Matthias, Liu, Duan, Luo, Chunqiao, Zhu, Hongjie, Mahmoudiandehkordi, Siamak, Neavin, Drew, Louie, Gregory, Dunlop, Boadie W., Frye, Mark A., Wang, Liewei, Weinshilboum, Richard M., Krishnan, Ranga R., Rush, A. John and Kaddurah-Daouk, Rima (2019). Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. Translational Psychiatry, 9 (1) 173, 1-14. doi: 10.1038/s41398-019-0507-5

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients

2019

Journal Article

Pharmacogenomic next-generation DNA sequencing: Lessons from the identification and functional characterization of variants of unknown significance in CYP2C9 and CYP2C19

Devarajan, Sandhya, Moon, Irene, Ho, Ming-Fen, Larson, Nicholas B., Neavin, Drew R., Moyer, Ann M., Black, John L., Bielinski, Suzette J., Scherer, Steven E., Wang, Liewei, Weinshilboum, Richard M. and Reid, Joel M. (2019). Pharmacogenomic next-generation DNA sequencing: Lessons from the identification and functional characterization of variants of unknown significance in CYP2C9 and CYP2C19. Drug Metabolism and Disposition, 47 (4), 425-435. doi: 10.1124/dmd.118.084269

Pharmacogenomic next-generation DNA sequencing: Lessons from the identification and functional characterization of variants of unknown significance in CYP2C9 and CYP2C19

2018

Journal Article

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: Metabolomics-informed genomics

Liu, Duan, Ray, Balmiki, Neavin, Drew R., Zhang, Jiabin, Athreya, Arjun P., Biernacka, Joanna M., Bobo, William V., Hall-Flavin, Daniel K., Skime, Michelle K., Zhu, Hongjie, Jenkins, Gregory D., Batzler, Anthony, Kalari, Krishna R., Boakye-Agyeman, Felix, Matson, Wayne R., Bhasin, Swati S., Mushiroda, Taisei, Nakamura, Yusuke, Kubo, Michiaki, Iyer, Ravishankar K., Wang, Liewei, Frye, Mark A., Kaddurah-Daouk, Rima and Weinshilboum, Richard M. (2018). Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: Metabolomics-informed genomics. Translational Psychiatry, 8 (1) 56, 8. doi: 10.1038/s41398-017-0056-8

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: Metabolomics-informed genomics

Funding

Current funding

  • 2026 - 2028
    Building the world's largest bipolar Stem Cell resource to elucidate disease risk and therapy response
    NHMRC IDEAS Grants
    Open grant
  • 2026 - 2030
    Stem cell model systems to reflect global diversity and unlock equitable cardiovascular disease research
    NHMRC Investigator Grants
    Open grant

Supervision

Availability

Dr Drew Neavin is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Supervision history

Current supervision

Media

Enquiries

For media enquiries about Dr Drew Neavin's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au